Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg)

Journal of Clinical Virology

Volumn 47, Issue 3, 2010, Pages 238-242

  Schüttler, Christian G ^a   Wend, Ulrike C ^a   Faupel, Fabian M ^a   Lelie, P Nico ^b   Gerlich, Wolfram H ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

HBsAg; HBV genotypes; Immune assay; International Standard

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

AMINO ACID SEQUENCE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME IMMUNOASSAY; GEL CHROMATOGRAPHY; HEPATITIS B VIRUS; IMMUNOELECTROPHORESIS; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; QUALITY CONTROL; ULTRACENTRIFUGATION; VIRUS CHARACTERIZATION; VIRUS PARTICLE; VIRUS PURIFICATION; WESTERN BLOTTING;

ANIMALS; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOASSAY; REFERENCE STANDARDS; ULTRACENTRIFUGATION; VIROLOGY;

EID: 76449115822     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.12.019     Document Type: Article

References (24)

1. Schaefer S., and Gerlich W.H. Structure, replication and laboratory diagnosis of HBV and HDV. In: Benhamou J.P., Rizzetto R., Reichen R., et al. (Eds). The textbook of hepatology: from basic science to clinical practice. 3rd ed. (2007), Blackwell Publishing, Oxford 823-849
2. Kleinman S.H., and Busch M.P. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol Suppl. 1 (2006) S23-S29
3. Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., Chen D.S., Colombo M., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49 (2008) 652-657
4. Scheiblauer H., Soboll H., and Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 78 Suppl. 1 (2006) S66-70
5. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44 (2006) 675-684
6. Gerlich W.H., Stamm B., and Thomssen R. Prognostic significance of quantitative HBsAg determination with acute hepatitis B. Verh Dtsch Ges Inn Med 83 (1977) 554-557
7. Erhardt A., Reineke U., Blondin D., Gerlich W.H., Adams O., Heintges R., et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 31 3 (2000) 716-722
8. Brunetto M.R., Moriconi F., Bonino F., Lau G.K., Farci P., Yurdaydin C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49 (2009) 1141-1150
9. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49 (2009) 1063-1065
10. Gerlich W.H., and Thomssen R. Standardized detection of hepatitis B surface antigen: determination of its serum concentration in weight units per volume. Develop Biol Standard vol. 30 (1975), S. Karger, Basel 78-87
11. Ferguson M., Pipkin P.A., Heath A.B., and Minor P.D. Working standards for hepatitis B surface antigen for use in the UK Blood Transfusion Service: results of a collaborative study. Vox Sang 65 (1993) 303-308
12. 15 chimpanzee-infectious doses of hepatitis B virus during preparation of a heat-inactivated hepatitis B vaccine. J Med Virol 23 (1987) 289-295
13. Ferguson M., Heath A., Lelie N., Nübling M., Nick S., Gerlich W., et al. WHO Working Group on Hepatitis and HIV Diagnostic Kits. Report of a collaborative study to (1) assess the suitability of a candidate replacement International Standard for HBsAg and a reference panel for HBsAg and (2) to calibrate the candidate standard in IU (2003). http://www.who.int/bloodproducts/cs/en/031987.pdf http://www.who.int/bloodproducts/cs/en/031987.pdf
14. WHO. 55th meeting of ECBS, Geneva 2004. Principles in the evaluation of HBsAg test kits: appropriate use of 2nd WHO International Standard (IS) and Reference Panel for HBsAg (2004). http://www.who.int/bloodproducts/publications/en/HBsAg_application_ECBS_2004.pdf http://www.who.int/bloodproducts/publications/en/HBsAg_application_ECBS_2004.pdf
15. Glebe D., and Gerlich W.H. Study of endocytosis and intracellular localization of subviral particles of HBV in primary hepatocytes. Methods Mol Med 96 (2004) 143-151
16. Gerlich W.H., Wend U., and Glebe D. Quantitative assay of hepatitis B surface antigen in serum or plasma using Laurell electrophoresis. In: Lau J., and Hamatake R. (Eds). Hepatitis B virus protocols book (2004), Humana Press, Totowa, NJ 57-63
17. Sobotta D., Sominskaya J., Jansons J., Meisel H., Schmitt S., Heermann K.H., et al. Mapping of immunodominant B-cell epitopes and the human serum albumin binding site in natural hepatitis B virus surface antigen of defined genosubtype. J Gen Virol 81 (2000) 369-378
18. Jursch C.A., Gerlich W.H., Glebe D., Schaefer S., Marie O., and Thraenhart O. Molecular approaches to validate disinfectants against hepatitis B virus. Med Microbiol Immunol 190 (2002) 189-197
19. Schildgen O., Sirma H., Funk A., Olotu C., Wend U.C., Hartmann H., et al. Variant of hepatitis B virus with primary resistance to Adefovir. New Engl J Med 354 (2006) 1807-1812
20. Norder H., Couroucé A.M., Coursaget P., Echevarria J.M., Lee S.D., Mushahwar I.K., et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47 (2004) 289-309
21. Heermann K.H., Goldmann U., Schwartz W., Seyffarth T., Baumgarten H., and Gerlich W.H. Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol 52 (1984) 396-402
22. Cameron C.H. What's in a nanogram?. Transfus Microbiol (Newsletter) 4 (1983) 8-10
23. Barbara J.H.J. Question of quality: how much HBsAg is there in this sample and is our assay sensitive enough to detect it?. Vox Sang 65 (1993) 249-250
24. Chudy M., Hanschmann K.-M., Kress J., Gerlich W., and Nübling M. Collaborative study to establish a World Health Organization international genotype panel for hepatitis b virus nucleic acid amplification technique (NAT)-based assays (2009)